Opus Genetics is trading 5.6% higher at $4.04 on October 20, alongside broader biotech-sector gains; no clear company-specific news was found to explain the move.
- XBI is up 2.10% during the regular session amid sector-wide M&A and positive clinical-trial sentiment.
- The company presented at the Chardan Healthcare Conference, where management discussed its pipeline and previously announced FDA approval of phentolamine.
- Price context shows a rebound after recent declines; today’s volume and trading activity were not provided.